TY - JOUR T1 - Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 1667 LP - 1672 DO - 10.1097/IGC.0000000000000818 VL - 26 IS - 9 AU - Dongge Cai AU - Hongli Sun AU - Yanhua Qi AU - Xiaogui Zhao AU - Minjuan Feng AU - Xiaoling Wu Y1 - 2016/11/01 UR - http://ijgc.bmj.com/content/26/9/1667.abstract N2 - Background Metformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus. In recent years, long-term administration of metformin has been found to reduce carcinogenic risk for cancers derived from various tissues. However, its cellular and molecular mechanisms of anticancer action in the endometrial cancer (EC) have not yet been fully elucidated.Patients and Methods Sixty patients diagnosed as endometrial carcinoma were grouped into (n = 30) and non-treatment mixed (n = 30) for analysis. Thirty healthy donors are control groups. We attempt to investigate the interaction of metformin, insulin-like growth factor 1 (IGF-1) expression, and phosphorylated mammalian target of rapamycin (p-mTOR) and AMP-activated protein kinase (p-AMPK).Results We found that high IGF-1 plasma concentrations in women with EC were reversed by conventional antidiabetic doses of metformin in the present work. In parallel, the activation of AMPK and suppression of mTOR seemed to play an important role for the effect of metformin in patients with EC.Conclusions This pilot trial presents biological evidence consistent with antiproliferative effects of metformin in women with EC in the clinical setting. ER -